OA10593A - Benzopyrans and their use as therapeutic agents - Google Patents

Benzopyrans and their use as therapeutic agents Download PDF

Info

Publication number: OA10593A
Authority: OA; OAPI
Prior art keywords: benzopyran; disease; dihydro; acetyl; pharmaceutically acceptable
Prior art date: 1994-06-10

Application number

OA60933A

Other languages

English (en)

Inventor

Wai Ngor Chan

Helen Kate Ann Morgan

Mervyn Thompson

John Morris Evans

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-06-10

Filing date

1996-12-10

Publication date

2002-07-10

1994-06-10 Priority claimed from GB9411632A external-priority patent/GB9411632D0/en

1994-06-13 Priority claimed from GB9411798A external-priority patent/GB9411798D0/en

1996-12-10 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2002-07-10 Publication of OA10593A publication Critical patent/OA10593A/en

Links

239000003814 drug Substances 0.000 title claims description 17
229940124597 therapeutic agent Drugs 0.000 title claims description 5
150000001562 benzopyrans Chemical class 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims abstract description 58
230000000694 effects Effects 0.000 claims abstract description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
208000035475 disorder Diseases 0.000 claims abstract description 19
238000011282 treatment Methods 0.000 claims abstract description 17
230000035939 shock Effects 0.000 claims abstract description 15
239000001961 anticonvulsive agent Substances 0.000 claims abstract description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 11
208000019695 Migraine disease Diseases 0.000 claims abstract description 11
208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims abstract description 11
206010027599 migraine Diseases 0.000 claims abstract description 11
239000000126 substance Substances 0.000 claims abstract description 11
206010026749 Mania Diseases 0.000 claims abstract description 10
208000018737 Parkinson disease Diseases 0.000 claims abstract description 10
206010015037 epilepsy Diseases 0.000 claims abstract description 10
230000001537 neural effect Effects 0.000 claims abstract description 10
201000000980 schizophrenia Diseases 0.000 claims abstract description 10
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 9
208000019901 Anxiety disease Diseases 0.000 claims abstract description 9
208000028017 Psychotic disease Diseases 0.000 claims abstract description 9
230000036506 anxiety Effects 0.000 claims abstract description 9
229960002715 nicotine Drugs 0.000 claims abstract description 9
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 9
208000024827 Alzheimer disease Diseases 0.000 claims abstract description 8
238000011321 prophylaxis Methods 0.000 claims abstract description 8
230000016571 aggressive behavior Effects 0.000 claims abstract description 7
238000000034 method Methods 0.000 claims description 25
208000028867 ischemia Diseases 0.000 claims description 10
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical class N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
239000003179 convulsant agent Substances 0.000 claims 1
230000000069 prophylactic effect Effects 0.000 claims 1
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
229940049706 benzodiazepine Drugs 0.000 abstract 1
150000001557 benzodiazepines Chemical class 0.000 abstract 1
229960003920 cocaine Drugs 0.000 abstract 1
GQFPOKZKVWOPGW-MSOLQXFVSA-N n-[(3s,4r)-7-acetyl-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-4-fluorobenzamide Chemical compound N([C@@H]1C2=CC=C(C=C2OC(C)(C)[C@H]1O)C(=O)C)C(=O)C1=CC=C(F)C=C1 GQFPOKZKVWOPGW-MSOLQXFVSA-N 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
239000000203 mixture Substances 0.000 description 18
239000003981 vehicle Substances 0.000 description 14
241000700159 Rattus Species 0.000 description 13
238000012360 testing method Methods 0.000 description 13
210000001367 artery Anatomy 0.000 description 11
229940079593 drug Drugs 0.000 description 11
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
210000004129 prosencephalon Anatomy 0.000 description 10
239000000243 solution Substances 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
210000004556 brain Anatomy 0.000 description 9
238000001356 surgical procedure Methods 0.000 description 9
206010047163 Vasospasm Diseases 0.000 description 8
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 8
XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
206010010904 Convulsion Diseases 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
239000008280 blood Substances 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
241000282472 Canis lupus familiaris Species 0.000 description 5
-1 colourants Substances 0.000 description 5
230000003111 delayed effect Effects 0.000 description 5
235000019441 ethanol Nutrition 0.000 description 5
239000010410 layer Substances 0.000 description 5
229960001412 pentobarbital Drugs 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
230000003997 social interaction Effects 0.000 description 5
206010061216 Infarction Diseases 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
230000001773 anti-convulsant effect Effects 0.000 description 4
229960003965 antiepileptics Drugs 0.000 description 4
230000000949 anxiolytic effect Effects 0.000 description 4
230000007574 infarction Effects 0.000 description 4
238000001802 infusion Methods 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
230000008961 swelling Effects 0.000 description 4
239000003826 tablet Substances 0.000 description 4
KPFXMYOQAANDKH-UHFFFAOYSA-N 2,3-dichloro-4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C(Cl)=C1Cl KPFXMYOQAANDKH-UHFFFAOYSA-N 0.000 description 3
IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 3
101150041968 CDC13 gene Proteins 0.000 description 3
235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 3
244000166102 Eucalyptus leucoxylon Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
230000037005 anaesthesia Effects 0.000 description 3
230000003276 anti-hypertensive effect Effects 0.000 description 3
239000002249 anxiolytic agent Substances 0.000 description 3
239000012267 brine Substances 0.000 description 3
230000001054 cortical effect Effects 0.000 description 3
239000013078 crystal Substances 0.000 description 3
CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 3
238000010828 elution Methods 0.000 description 3
239000000945 filler Substances 0.000 description 3
230000003447 ipsilateral effect Effects 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
235000010981 methylcellulose Nutrition 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
239000012044 organic layer Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241000699684 Meriones unguiculatus Species 0.000 description 2
229920005439 Perspex® Polymers 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
238000001949 anaesthesia Methods 0.000 description 2
230000002460 anti-migrenic effect Effects 0.000 description 2
230000000338 anxiogenic effect Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
238000010241 blood sampling Methods 0.000 description 2
239000002775 capsule Substances 0.000 description 2
210000001715 carotid artery Anatomy 0.000 description 2
238000007428 craniotomy Methods 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000010191 image analysis Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
229940113115 polyethylene glycol 200 Drugs 0.000 description 2
239000004926 polymethyl methacrylate Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000011002 quantification Methods 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
210000003625 skull Anatomy 0.000 description 2
238000003892 spreading Methods 0.000 description 2
230000007480 spreading Effects 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
238000005303 weighing Methods 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
PVPBBTJXIKFICP-UHFFFAOYSA-N (7-aminophenothiazin-3-ylidene)azanium;chloride Chemical compound [Cl-].C1=CC(=[NH2+])C=C2SC3=CC(N)=CC=C3N=C21 PVPBBTJXIKFICP-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
NPXCSDPOOVOVDQ-UHFFFAOYSA-N 1,2-dichloro-3-fluorobenzene Chemical compound FC1=CC=CC(Cl)=C1Cl NPXCSDPOOVOVDQ-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
LKXADRQJLNYNQL-UHFFFAOYSA-N 2h-chromen-3-ol Chemical compound C1=CC=C2OCC(O)=CC2=C1 LKXADRQJLNYNQL-UHFFFAOYSA-N 0.000 description 1
FEAVXMPFTQROEI-UHFFFAOYSA-N 2h-pyrano[3,2-b]pyridine Chemical class C1=CN=C2C=CCOC2=C1 FEAVXMPFTQROEI-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010048962 Brain oedema Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
239000005708 Sodium hypochlorite Substances 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
108010076830 Thionins Proteins 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
235000010210 aluminium Nutrition 0.000 description 1
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000000648 anti-parkinson Effects 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
210000001841 basilar artery Anatomy 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
208000006752 brain edema Diseases 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000013058 crude material Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000011833 dog model Methods 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
238000009297 electrocoagulation Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
LGLLXTFYYXSARU-PMACEKPBSA-N ethyl (2s)-2-[[(2s)-2-acetamido-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-3-methylbutanoate Chemical compound CCOC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(C)=O)CC1=CC=C(N(CCCl)CCCl)C=C1 LGLLXTFYYXSARU-PMACEKPBSA-N 0.000 description 1
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000004868 gas analysis Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000003370 grooming effect Effects 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
230000002262 irrigation Effects 0.000 description 1
238000003973 irrigation Methods 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000006742 locomotor activity Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000002698 mandibular nerve Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000036651 mood Effects 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
208000030459 obsessive-compulsive personality disease Diseases 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000000956 olfactory bulb Anatomy 0.000 description 1
210000002475 olfactory pathway Anatomy 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
208000007656 osteochondritis dissecans Diseases 0.000 description 1
150000002924 oxiranes Chemical class 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000216 proconvulsive effect Effects 0.000 description 1
OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229940068944 providone-iodine Drugs 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000001991 scapula Anatomy 0.000 description 1
238000007789 sealing Methods 0.000 description 1
SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
201000009032 substance abuse Diseases 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical class C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 1
229960001844 tubocurarine Drugs 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
238000010865 video microscopy Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Psychiatry (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrane Compounds (AREA)

OA60933A 1994-06-10 1996-12-10 Benzopyrans and their use as therapeutic agents OA10593A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB9411632A GB9411632D0 (en)	1994-06-10	1994-06-10	Novel treatment
GB9411798A GB9411798D0 (en)	1994-06-13	1994-06-13	Novel treatment

Publications (1)

Publication Number	Publication Date
OA10593A true OA10593A (en)	2002-07-10

Family

ID=26305044

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA60933A OA10593A (en)	1994-06-10	1996-12-10	Benzopyrans and their use as therapeutic agents

Country Status (29)

Country	Link
US (1)	US5760074A (de)
EP (2)	EP1114821B1 (de)
JP (2)	JP3575767B2 (de)
KR (1)	KR100397721B1 (de)
CN (2)	CN1174975C (de)
AP (1)	AP714A (de)
AT (2)	ATE250052T1 (de)
AU (1)	AU701060B2 (de)
BG (1)	BG63339B1 (de)
BR (1)	BR9507980A (de)
CA (1)	CA2192480C (de)
CY (1)	CY2508B1 (de)
CZ (1)	CZ286081B6 (de)
DE (2)	DE69524871T2 (de)
DK (2)	DK0764157T3 (de)
ES (2)	ES2207590T3 (de)
FI (1)	FI120686B (de)
HK (1)	HK1039115B (de)
HU (1)	HUT76136A (de)
NO (1)	NO315651B1 (de)
NZ (1)	NZ287872A (de)
OA (1)	OA10593A (de)
PL (1)	PL188134B1 (de)
PT (2)	PT1114821E (de)
RO (1)	RO113463B1 (de)
SG (1)	SG67930A1 (de)
SI (2)	SI0764157T1 (de)
SK (1)	SK281456B6 (de)
WO (1)	WO1995034545A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010021780A1 (en) *	1992-12-11	2001-09-13	Smithkline Beecham P.L.C.	Pharmaceutical composition containing bicyclic type compounds
GB9411635D0 (en) *	1994-06-10	1994-08-03	Smithkline Beecham Plc	Novel treatment
US6492415B2 (en) *	1996-09-18	2002-12-10	Smithkline Beecham P.L.C.	Use of benzopyranols to treat neurological disorders
GB9619492D0 (en) *	1996-09-18	1996-10-30	Smithkline Beecham Plc	Novel treatment
GB9726543D0 (en) *	1997-12-16	1998-02-11	Smithkline Beecham Plc	Novel compositions
GB9813949D0 (en) *	1998-06-29	1998-08-26	Smithkline Beecham Plc	Novel compounds
GB0028697D0 (en) *	2000-11-23	2001-01-10	S P A	Novel process
CA2602267A1 (en) *	2005-04-04	2006-10-12	Takeda Pharmaceutical Company Limited	Use of ramelteon to treat and prevent depression and anxiety disorders
WO2009147441A2 (en) *	2008-06-05	2009-12-10	Minster Research Limited	Novel treatments
CA2726878A1 (en) *	2008-06-05	2009-12-10	Minster Research Limited	Novel treatments
WO2011067607A1 (en)	2009-12-03	2011-06-09	Minster Research Ltd	Treatment of infectious diseases
EP2506846A1 (de)	2009-12-03	2012-10-10	Proximagen Limited	Behandlung von allodynie und hyperalgesie
US9499510B2 (en)	2012-07-03	2016-11-22	Proximagen Limited	Pro-drug compounds
GB201304814D0 (en) *	2013-03-15	2013-05-01	Proximagen Ltd	Pro-drug compounds
GB201322934D0 (en)	2013-12-23	2014-02-12	Proximagen Ltd	Prodrug compounds
GB201322932D0 (en) *	2013-12-23	2014-02-12	Proximagen Ltd	Pro-drug compounds
US12667586B2 (en)	2023-03-07	2026-06-30	Glaukos Corporation	Treatments for ocular surface disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0126311B1 (de) *	1983-05-18	1989-09-13	Beecham Group Plc	Benzopyran-Derivate.
GB9112721D0 (en) *	1991-06-13	1991-07-31	Smithkline Beecham Plc	Novel treatment
DE69327965T2 (de) *	1992-12-11	2000-10-19	Smithkline Beecham Corp., Philadelphia	Pharmazeutische zusammenstellung enthaltende bizyklisch typ verbindungen
KR100326968B1 (ko) *	1992-12-11	2002-07-27	스미스클라인비이참피이엘시이	약학적 활성을 가진 이환식 화합물
US5536718A (en) *	1995-01-17	1996-07-16	American Cyanamid Company	Tricyclic benzazepine vasopressin antagonists

1995
- 1995-05-31 DE DE69524871T patent/DE69524871T2/de not_active Expired - Lifetime
- 1995-05-31 ES ES01200801T patent/ES2207590T3/es not_active Expired - Lifetime
- 1995-05-31 EP EP01200801A patent/EP1114821B1/de not_active Expired - Lifetime
- 1995-05-31 DE DE69531801T patent/DE69531801T2/de not_active Expired - Lifetime
- 1995-05-31 KR KR1019960707048A patent/KR100397721B1/ko not_active Expired - Lifetime
- 1995-05-31 SI SI9530579T patent/SI0764157T1/xx unknown
- 1995-05-31 CA CA002192480A patent/CA2192480C/en not_active Expired - Lifetime
- 1995-05-31 NZ NZ287872A patent/NZ287872A/en not_active IP Right Cessation
- 1995-05-31 EP EP95921798A patent/EP0764157B1/de not_active Expired - Lifetime
- 1995-05-31 PT PT01200801T patent/PT1114821E/pt unknown
- 1995-05-31 DK DK95921798T patent/DK0764157T3/da active
- 1995-05-31 PL PL95317579A patent/PL188134B1/pl unknown
- 1995-05-31 CZ CZ19963617A patent/CZ286081B6/cs not_active IP Right Cessation
- 1995-05-31 AP APAP/P/1996/000889A patent/AP714A/en active
- 1995-05-31 SK SK1587-96A patent/SK281456B6/sk not_active IP Right Cessation
- 1995-05-31 SG SG1996008495A patent/SG67930A1/en unknown
- 1995-05-31 RO RO96-02326A patent/RO113463B1/ro unknown
- 1995-05-31 JP JP50155696A patent/JP3575767B2/ja not_active Expired - Lifetime
- 1995-05-31 HU HU9603415A patent/HUT76136A/hu not_active Application Discontinuation
- 1995-05-31 SI SI9530691T patent/SI1114821T1/xx unknown
- 1995-05-31 PT PT95921798T patent/PT764157E/pt unknown
- 1995-05-31 AU AU26727/95A patent/AU701060B2/en not_active Expired
- 1995-05-31 ES ES95921798T patent/ES2170798T3/es not_active Expired - Lifetime
- 1995-05-31 CN CNB951944134A patent/CN1174975C/zh not_active Expired - Lifetime
- 1995-05-31 AT AT01200801T patent/ATE250052T1/de active
- 1995-05-31 AT AT95921798T patent/ATE211469T1/de active
- 1995-05-31 BR BR9507980A patent/BR9507980A/pt not_active IP Right Cessation
- 1995-05-31 DK DK01200801T patent/DK1114821T3/da active
- 1995-05-31 CN CNB01124366XA patent/CN1234702C/zh not_active Expired - Lifetime
- 1995-05-31 WO PCT/EP1995/002076 patent/WO1995034545A1/en not_active Ceased
- 1995-06-02 US US08/460,151 patent/US5760074A/en not_active Expired - Lifetime
1996
- 1996-12-09 NO NO19965260A patent/NO315651B1/no not_active IP Right Cessation
- 1996-12-10 OA OA60933A patent/OA10593A/en unknown
- 1996-12-10 FI FI964936A patent/FI120686B/fi not_active IP Right Cessation
- 1996-12-10 BG BG101040A patent/BG63339B1/bg unknown
2002
- 2002-01-10 HK HK02100192.4A patent/HK1039115B/en not_active IP Right Cessation
2003
- 2003-01-23 JP JP2003014984A patent/JP2003238554A/ja active Pending
2005
- 2005-03-15 CY CY0500017A patent/CY2508B1/xx unknown

Also Published As

Publication number	Publication date
HUT76136A (en)	1997-06-30
BG101040A (en)	1997-08-29
DE69531801T2 (de)	2004-07-01
AP9600889A0 (en)	1997-01-31
JP2003238554A (ja)	2003-08-27
HU9603415D0 (en)	1997-02-28
DK1114821T3 (da)	2004-02-02
SI0764157T1 (en)	2002-06-30
DK0764157T3 (da)	2002-04-22
WO1995034545A1 (en)	1995-12-21
ATE250052T1 (de)	2003-10-15
NO315651B1 (no)	2003-10-06
ES2207590T3 (es)	2004-06-01
BG63339B1 (bg)	2001-10-31
CA2192480C (en)	2007-07-24
FI120686B (fi)	2010-01-29
CN1336369A (zh)	2002-02-20
AU2672795A (en)	1996-01-05
ATE211469T1 (de)	2002-01-15
BR9507980A (pt)	1997-08-12
EP1114821A1 (de)	2001-07-11
HK1039115B (en)	2004-08-13
RO113463B1 (ro)	1998-07-30
ES2170798T3 (es)	2002-08-16
SK281456B6 (sk)	2001-03-12
CA2192480A1 (en)	1995-12-21
PL317579A1 (en)	1997-04-14
EP1114821B1 (de)	2003-09-17
NO965260D0 (no)	1996-12-09
EP0764157B1 (de)	2002-01-02
HK1039115A1 (en)	2002-04-12
JPH10501251A (ja)	1998-02-03
DE69524871T2 (de)	2002-08-22
KR100397721B1 (ko)	2004-04-28
NO965260L (no)	1997-02-06
AP714A (en)	1998-12-23
CN1174975C (zh)	2004-11-10
US5760074A (en)	1998-06-02
PL188134B1 (pl)	2004-12-31
PT1114821E (pt)	2004-02-27
JP3575767B2 (ja)	2004-10-13
EP0764157A1 (de)	1997-03-26
FI964936L (fi)	1997-02-06
CN1234702C (zh)	2006-01-04
SK158796A3 (en)	1997-07-09
SG67930A1 (en)	1999-10-19
DE69531801D1 (de)	2003-10-23
CY2508B1 (en)	2005-12-23
CN1154698A (zh)	1997-07-16
AU701060B2 (en)	1999-01-21
NZ287872A (en)	1998-05-27
PT764157E (pt)	2002-06-28
FI964936A0 (fi)	1996-12-10
CZ286081B6 (cs)	2000-01-12
SI1114821T1 (en)	2004-02-29
HK1001286A1 (en)	1998-06-12
CZ361796A3 (en)	1997-08-13
DE69524871D1 (de)	2002-02-07

Publication	Publication Date	Title
AP714A (en)	1998-12-23	Benzopyrans and their use as therapeutic agents.
EP0673374B1 (de)	2000-03-01	Pharmazeutische zusammenstellung enthaltende bizyklisch typ verbindungen
AU679475B2 (en)	1997-07-03	Bicyclic compounds with pharmaceutical activity
WO1994013292A1 (en)	1994-06-23	Potassium channel activators for use in therapy
EP0764158B1 (de)	2002-09-18	Benzopyrane und deren verwendung als therapeutische mittel
EP0764159A1 (de)	1997-03-26	C-4 amid substituierte verbindungen und deren verwendung als therapeutische mittel
AU739678B2 (en)	2001-10-18	Benzopyrans and their use as therapeutic agents
CA2151507C (en)	2006-10-03	Pharmaceutical composition containing bicyclic type compounds
WO1994013297A1 (en)	1994-06-23	Potassium channel activators and use thereof in therapy
US20020123630A1 (en)	2002-09-05	Pharmaceutical composition containing bicyclic type compounds
HK1012377B (en)	2000-11-24	Pharmaceutical composition containing bicyclic type compounds